Kymera Therapeutics (KYMR) Non-Current Deffered Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has 7 years of Non-Current Deffered Revenue data on file, last reported at $11.4 million in Q4 2025.

• Non-Current Deffered Revenue for Q4 2025 came in at $11.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $11.4 million (changed N/A YoY), and the FY2025 annual result was $11.4 million, changed N/A from the prior year.
• Non-Current Deffered Revenue eased to $11.4 million in Q4 2025 per KYMR's latest filing, from $14.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $64.7 million in Q1 2021 and troughed at $3.2 million in Q2 2024.
• A 5-year average of $27.6 million and a median of $23.9 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• On a YoY basis, Non-Current Deffered Revenue climbed as much as 4.36% in 2024 and fell as far as 84.38% in 2024.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $39.3 million in 2021, then declined by 28.74% to $28.0 million in 2022, then sank by 40.11% to $16.8 million in 2023, then sank by 80.98% to $3.2 million in 2024, then soared by 258.73% to $11.4 million in 2025.
• Business Quant data shows KYMR's Non-Current Deffered Revenue at $11.4 million in Q4 2025, $14.0 million in Q3 2025, and $3.2 million in Q2 2024.